The Nobel Assembly at Karolinska Institutet has awarded the 2026 Nobel Prize in Physiology or Medicine to three scientists “for their discoveries concerning light-gated ion channels and optogenetics”. It was jointly presented to Karl Deisseroth, The Howard Hughes Medical Institute and Stanford University, USA; Peter Hegemann, Humboldt… Read More
Results of an investigators’ Phase II clinical trial in vitamin C have been published by Wiley online in Cancer, a peer-reviewed journal of the American Cancer Society. Vitamin C boosts the activity of cellular proteins called TET enzymes that help control which genes are turned on or off. Because decreased… Read More
An open letter from the chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi has urged European governments to create conditions that attract investment in next-generation medicines. They argue that Europe is losing ground to global competition, with over $600 billion in… Read More
The European Commission (EC) has granted marketing authorisation under exceptional circumstances for Nezglyal (leriglitazone), an orally bioavailable, brain penetrating, selective PPAR gamma agonist, as a treatment for male cALD patients. It is approved in patients aged two to 12 years with Gadolinium (Gd)-negative brain lesions and is… Read More
US researchers have filed a class action lawsuit challenging the National Institutes of Health’s (NIH) policy of blocking grants to censor views it disagrees with, on everything from DEI to gender identity to climate change. The plaintiffs are represented by the American Civil Liberties Union, the ACLU… Read More
Experts from across the drug discovery ecosystem will explore the technologies, strategies, therapies and investment trends shaping early-stage drug discovery at the Drug Discovery Innovators & Investors (DDII) Digital Forum on 30 September. The Forum is free to attend. Register for the full event, or simply join one of the… Read More
Transgene and NEC Corporation have reported sustained 100% three-year disease-free survival (DFS) in patients treated with TG4050 in the Phase I part of a randomised Phase I/II trial. TG4050 is the first individualised neoantigen therapeutic vaccine (INTV) based on the myvac platform. It is… Read More
The US Food and Drug Administration (FDA) has approved Revolution Medicines’ Rasonque (daraxonrasib) once-daily oral tablets, for the treatment of adults with metastatic pancreatic adenocarcinoma (PDAC). It is approved in patients who have received at least one prior systemic therapy or who are not candidates for multiagent… Read More
NRG Therapeutics has shared preclinical and mechanistic data of its lead clinical asset NRG5051, a treatment for amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), and Parkinson’s. NRG disclosed that NRG5051, a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition… Read More
Pancreatic tumours can resist immunotherapy by recruiting nearby immune cells, according to new research, which has revealed a potential new strategy for overcoming resistance in cell therapies. CAR T-cell therapy has transformed treatment for several blood cancers but has repeatedly stalled against solid tumours such as pancreatic… Read More
Scientists have identified a brief window after brain tumour surgery during which a treatment for glioblastoma can cross the brain’s protective barrier and reach the cancer cells most likely to trigger tumour regrowth. The discovery could pave the way for more effective treatments for glioblastoma, the most… Read More
AC Immune has received Fast Track designation and clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) for its anti-alpha-synuclein (a-syn) active immunotherapy candidate, ACI-7104, for the treatment of early-stage Parkinson’s disease (PD). ACI-7104 is designed to induce… Read More
A little‑known group of hard-to-find immune cells could help transform cancer treatment, scientists at the University of Manchester’s Cancer Research UK Manchester Institute, have found. Their discovery, published in Immunity, centres on activated dendritic cells, a specialised population of immune cells that orchestrate the body’s… Read More
BioVie has announced results from its Phase II SUNRISE-PD trial evaluating its drug candidate bezisterim in early-stage Parkinson’s disease (PD). The SUNRISE-PD trial was a Phase II, multicentre, randomised, double-blind, placebo-controlled trial designed to establish proof-of-mechanism and proof-of-concept in patients with early-stage PD that had not previously… Read More
A targeted antibody therapy combined with standard chemotherapy has shown early signs of tumour shrinkage and disease control in patients with advanced bowel cancer. This is according to new Phase I clinical trial results from The Institute of Cancer Research, London and The Royal Marsden NHS Foundation… Read More
Following Health Canada’s authorisation, the first participants have been vaccinated in Moderna’s Phase I clinical study evaluating mRNA-1469, an mRNA vaccine to prevent Bundibugyo ebolavirus (BDBV). “Vaccinating the first participants with mRNA-1469 marks an important milestone in advancing a vaccine candidate against Bundibugyo ebolavirus, for which no… Read More
